How Applicable Is Mobile Health Tecnology Beyond Southeast Asia, Where Your Research Has Been Focused?

Read Transcript

So my focus in south Asia certainly has been for the past decade and a half, but Globally, Africa has really been a leader in the mHealth space, we've seen political initiatives where governments, ministers as we have here today at the get health summit mobilize a massive energy that's coming both from the private sector and from the public sector, to bring to bear some of these innovation and some of these resources to transform health systems.

I think we are seeing these technologies as being used for education so educating front line providers, providing training beyond the bounds of the clinic and the infrequent opportunities to provide formal classroom based education also extending those opportunities to wherever those community workers go once they receive that initial training.

Keeping them connected to the latest practices and the best standard of care that is applicable for them and in their context. I think we've seen, and coming back to that political rule I spoke about. That's really a critical component to make any of these happen in a particular country.

A couple of months ago there was a moratorium declared in Uganda by the Ministry of Health, because of the against proliferation of new E-Health or M-Health projects because there was concern that there was lack of coordination across this project, that there was redundancy or duplication in efforts that was being implemented by different agencies across this country.

To some extent that's frustrating as a researcher, you're engaged in some of these projects which are testing new innovations which are helping to develop strategies appropriate for that population. But at the same time I think we understand that requisite from the ministry to have some level of coordination across projects some level of alignment with national strategy so that the innovations that had been made across the board actually can be integrated into a common strategy and then be scaled when we have the evidence to move forward.